A Phase 1, First-in-human Study of the Safety, Single- and Multiple-Dose Pharmacokinetics, and Preliminary Activity of Escalating Doses of RBN-2397, an Oral PARP7 Inhibitor, in Patients with Solid Tumors
This Study is
No Longer Enrolling
Details
Age
Adult
Eligibility
enrolling to Expansion cohorts only: SCCL, HNSCC, HR+ breast cancer, and PARP7 amplified cancer.
Type of Study
Treatment
Locations
University of Colorado Hospital
Study ID
Protocol Number: 21-3286
More information available at ClinicalTrials.gov: NCT04053673
Categories
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers